PL2230932T3 - Powlekany preparat farmaceutyczny lub nutraceutyczny o zwiększonym uwalnianiu substancji aktywnej w jelicie grubym - Google Patents

Powlekany preparat farmaceutyczny lub nutraceutyczny o zwiększonym uwalnianiu substancji aktywnej w jelicie grubym

Info

Publication number
PL2230932T3
PL2230932T3 PL08708546T PL08708546T PL2230932T3 PL 2230932 T3 PL2230932 T3 PL 2230932T3 PL 08708546 T PL08708546 T PL 08708546T PL 08708546 T PL08708546 T PL 08708546T PL 2230932 T3 PL2230932 T3 PL 2230932T3
Authority
PL
Poland
Prior art keywords
active substance
large intestine
increased release
coated pharmaceutical
nutraceutical preparation
Prior art date
Application number
PL08708546T
Other languages
English (en)
Inventor
Hema Ravishankar
Shradda Bodinge
Hans-Ulrich Petereit
Original Assignee
Evonik Röhm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Röhm Gmbh filed Critical Evonik Röhm Gmbh
Publication of PL2230932T3 publication Critical patent/PL2230932T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
    • A23L27/72—Encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08708546T 2008-01-10 2008-02-01 Powlekany preparat farmaceutyczny lub nutraceutyczny o zwiększonym uwalnianiu substancji aktywnej w jelicie grubym PL2230932T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN95CH2008 2008-01-10

Publications (1)

Publication Number Publication Date
PL2230932T3 true PL2230932T3 (pl) 2017-09-29

Family

ID=39798120

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08708546T PL2230932T3 (pl) 2008-01-10 2008-02-01 Powlekany preparat farmaceutyczny lub nutraceutyczny o zwiększonym uwalnianiu substancji aktywnej w jelicie grubym

Country Status (14)

Country Link
US (1) US9237760B2 (pl)
EP (1) EP2230932B1 (pl)
JP (1) JP5409651B2 (pl)
KR (1) KR101500792B1 (pl)
CN (1) CN101877971A (pl)
BR (1) BRPI0822026B8 (pl)
CA (1) CA2711473C (pl)
ES (1) ES2626078T3 (pl)
HU (1) HUE034848T2 (pl)
IL (1) IL205488A (pl)
MX (1) MX2010007577A (pl)
PL (1) PL2230932T3 (pl)
SI (1) SI2230932T1 (pl)
WO (1) WO2009086940A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2152250T3 (pl) 2007-05-07 2020-06-15 Evonik Röhm Gmbh Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku
WO2013144176A1 (en) * 2012-03-30 2013-10-03 Laboratorios Del Dr. Esteve, S.A. Controlled release formulatin comprising mesalamine
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
WO2016046817A1 (en) * 2014-09-24 2016-03-31 Vital Beverages Global Inc. Compositions and methods for selective gi tract delivery
EP3218349A2 (en) 2014-11-14 2017-09-20 Gemphire Therapeutics Inc. Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers
CA2986188A1 (en) 2015-06-05 2016-12-08 Evonik Rohm Gmbh Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
UA125747C2 (uk) 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
US20190111001A1 (en) * 2016-03-30 2019-04-18 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3612171A4 (en) 2017-04-18 2020-10-21 Gemphire Therapeutics Inc. GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME
WO2018209257A1 (en) * 2017-05-11 2018-11-15 Gemphire Therapeutics Inc. Gemcabene compositions and methods of use thereof
JP7336187B2 (ja) * 2017-11-30 2023-08-31 日本ケミファ株式会社 多層構造を有する粒子状医薬組成物
ES2975442T3 (es) 2019-12-11 2024-07-05 Evonik Operations Gmbh Forma farmacéutica para su uso en el tratamiento o la prevención de una enfermedad
US20230102999A1 (en) 2020-01-10 2023-03-30 First Wave Bio, Inc. Deuterated niclosamide
TW202200121A (zh) 2020-03-16 2022-01-01 美商費斯特威弗生技股份有限公司 治療方法
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
KR20250100660A (ko) 2022-10-25 2025-07-03 베라더믹스 인코포레이티드 변형 방출 미녹시딜의 조성물 및 사용 방법
CN118892464A (zh) * 2023-05-02 2024-11-05 雅典娜制药股份有限公司 美沙拉秦缓释组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
FR2759293B1 (fr) 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
DE10250543A1 (de) 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
MXPA04010956A (es) 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
DE10353196A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
DE10353186A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
CA2661561C (en) 2006-08-18 2013-12-24 Evonik Operations Gmbh Pharmaceutical composition with controlled active ingredient delivery for active ingredients with good solubility in water
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
PL2152250T3 (pl) 2007-05-07 2020-06-15 Evonik Röhm Gmbh Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku

Also Published As

Publication number Publication date
CA2711473C (en) 2016-01-26
BRPI0822026B1 (pt) 2019-05-07
KR20100103566A (ko) 2010-09-27
BRPI0822026B8 (pt) 2021-05-25
SI2230932T1 (sl) 2017-07-31
WO2009086940A1 (en) 2009-07-16
CA2711473A1 (en) 2009-07-16
KR101500792B1 (ko) 2015-03-09
BRPI0822026A2 (pt) 2014-10-07
EP2230932B1 (en) 2017-03-29
US20100247639A1 (en) 2010-09-30
JP5409651B2 (ja) 2014-02-05
IL205488A (en) 2016-08-31
HUE034848T2 (en) 2018-03-28
US9237760B2 (en) 2016-01-19
IL205488A0 (en) 2010-12-30
JP2011509264A (ja) 2011-03-24
ES2626078T3 (es) 2017-07-21
MX2010007577A (es) 2010-08-04
CN101877971A (zh) 2010-11-03
EP2230932A1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
IL275854A (en) Pharmaceutical composition and its administration
SI2230932T1 (sl) Oplaščeni farmacevtski ali nutracevtski pripravek s povečanim sproščanjem aktivne učinkovine v črevesu
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
DK2346495T4 (da) Farmaceutisk formulering 514
HUE069458T2 (hu) Terápiás hatóanyagok bejuttatására szolgáló új lipidek és készítmények
ZA201101477B (en) Co-crystals and pharmaceutical formulations comprising the same
BRPI0907914A2 (pt) Tiras de filme comestível com ingrediente ativo com liberação modificada
EP2474522A4 (en) AGOME ELITE AND PHARMACEUTICAL COMPOSITIONS THEREOF
IL250259A0 (en) Compositions comprising ursolic acid and derivatives thereof and uses thereof
BRPI0917358A2 (pt) formulação farmacêutica de liberação controlada e método.
BR112012013148A2 (pt) formulação farmacêutica e uso
BRPI0814851A2 (pt) Combinações de substâncias ativas com propriedades inseticidsa e acaricidas
HRP20190031T1 (hr) Sintetski triterpenoidi i postupci njihove upotrebe u liječenju bolesti
BRPI0913822A2 (pt) forma farmacêutica oral e uso da forma farmacêutica
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0921654A2 (pt) formulação farmacêutica
EP2154966A4 (en) BENZIMIDAZOLE AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
PL2379086T3 (pl) Preparat farmeceutyczny
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
HUE040391T2 (hu) Mikroszemcsékbõl készített lassú hatóanyag-kibocsátású gyógyszerkészítmények
PL2651409T3 (pl) Nowa kompozycja farmaceutyczna zawierająca nlpz i cyklodekstrynę
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
BR112013010709A2 (pt) derivado de ácido trans-2-decenoico e agente farmacêutico contendo o mesmo
BR112012016736A2 (pt) composição , formulação farmacêutica e uso da composição"
IL205550A0 (en) Coated pharmaceutical or nutraceutical preparation with enhanced pulsed active substance release